Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

BACKGROUND: Eribulin mesylate is a nontaxane microtubule dynamics inhibitor approved for second-line (European Union) or third-line (United States) treatment of metastatic breast cancer. Two phase 2 single trials, evaluating first-line eribulin as monotherapy (Study 206; NCT01268150) or in combinati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Schwartzberg, Lee, McIntyre, Kristi, Wilks, Sharon, Puhalla, Shannon, O’Shaughnessy, Joyce, Berrak, Erhan, He, Yaohua, Vahdat, Linda
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567408/
https://ncbi.nlm.nih.gov/pubmed/31195996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5674-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados